Results 51 to 60 of about 102,210 (307)

Warfarin time in therapeutic range of primary healthcare patients in the Western Cape Province, South Africa

British Journal of Clinical Pharmacology, EarlyView.
Introduction Warfarin therapy is the mainstay of anticoagulation treatment in South Africa and requires frequent INR monitoring due to interindividual patient variability. Time in therapeutic range (TTR) reflects the proportion of total treatment time during which INR values are within therapeutic range.
Masudah Paleker, Christopher Kelly, Robin Dyers, Eric Decloedt   +3 more
wiley   +1 more source

Awareness of subconjunctival bleeding on warfarin therapy patient [PDF]

, 2010
A case of subconjunctival bleeding as an initial sign of progressive bleeding caused by warfarin therapy on patient with mitralregurgitation, its clinical signs, multidisciplinary approach and management.
Diana Haryati Kusumastuti, -, Dewi Rosalina, -, Ratna Doemilah, -, Evelyn Komaratih, -   +3 more
core   +1 more source

Warfarin Resisance and Recurrent Thrombosis in an Iranian Patient

Case Reports in Clinical Practice, 2019
Warfarin resisance was known as subtherapeutic INR (International Normalized Ratio) in spite of normally prescribed doses of warfarin. There are few reports of warfarin resisance from Iran.
Masuod Malekzadeh, Marzieh Pazoki
doaj  

Profile and outcome of patients with Warfarin Toxicity admitted in a tertiary care hospital in Bhutan: a cross-sectional study investigators and institutions

BMC Research Notes, 2023
Objective To study the profile, clinical presentation and outcome of hospital stay among patients admitted with warfarin toxicity at the Jigme Dorji Wangchuck National Referral Hospital, Bhutan.
Yeshey Penjore, Thinley Dorji, Sangay Dorji, Saran Tenzin Tamang   +3 more
doaj   +1 more source

Clinical relevance of pharmacogenomic information for improving prescribing practices in acutely admitted older medical patients

British Journal of Clinical Pharmacology, EarlyView.
Aims Safe prescribing and effective medication review during acute hospitalization depends on accurate information about liver and kidney function because these organs are responsible for the elimination of most medications. While estimates for kidney function are widely used, comparable markers of hepatic drug‐metabolizing capacity are not routinely ...
Louise Westberg Strejby Christensen, Anne Kirstine Boas, Emilie Clausen, Nicoline Elers Koch, Anne Byriel Walls, Lotte Stig Nørgaard, Michael Asger Andersen, Anissa Aharaz, Rikke Lundsgaard Nielsen, Olivia Bornæs, Juliette Tavenier, Baker Nawfal Jawad, Helle Gybel Juul‐Larsen, Esben Iversen, Ove Andersen, Lona Louring Christrup, Kim Peder Dalhoff, Morten Baltzer Houlind   +17 more
wiley   +1 more source

Non-valvular atrial fibrillation and stroke : implications for management [PDF]

, 1995
Nonvalvular Atrial Fibrillation is more prevalent with increasing age. It is associated with a six-fold excess risk of stroke; and a cumulative lifetime stroke risk of 35%. 15% of ischaemic strokes are directly attributable to it.
Tilney, Myra Kay
core  

Comparing outcomes using low‐dose apixaban and anti‐Xa monitoring and vitamin K antagonists in patients with renal replacement therapy

British Journal of Clinical Pharmacology, EarlyView.
Background Guidelines recommend oral anticoagulation for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Outside the United States, apixaban is unlicensed for use in patients with end‐stage renal disease (ESRD) receiving renal replacement therapy (RRT).
John K. Bartoli‐Abdou, Alexander T. Cohen, Lucy Vernon, Victoria Collings, Ubonphan Chaichana, Natasha Moore, Hamda Jibril, Li Wei, Nicola Kumar, Karen A. Breen, Andrew J. Doyle   +10 more
wiley   +1 more source

Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population

BMC Cardiovascular Disorders, 2019
Background Clinical trials have demonstrated that direct oral anticoagulants (DOACs) are at least non-inferior to warfarin in reducing the risk of stroke/systemic embolism (SE) among patients with non-valvular atrial fibrillation (NVAF), but the ...
Kiran Gupta, Jeffrey Trocio, Allison Keshishian, Qisu Zhang, Oluwaseyi Dina, Jack Mardekian, Anagha Nadkarni, Thomas C Shank   +7 more
doaj   +1 more source

Warfarin interactions: a letter to editor [PDF]

Patient Safety and Quality Improvement Journal, 2019
Today, with the advances in the treatment of cardiovascular patients such as intravascular stents, cardiac valves and intraventricular pacing and heart transplantation, many patients require the use of anticoagulants such as warfarin, sprain, Plavix ...
Sayyed Majid Sadrzadeh, Elnaz Vafadar Moradi, Seyed Mohammad Mousavi, Behrang Rezvani Kakhki, Shaghayegh Rahmani   +4 more
doaj   +1 more source

Harnessing blood clot as a native scaffold for orchestrating tissue repairs and regeneration

BMEMat, EarlyView.
The blood clot, owing to its dynamic composition and unique microenvironment, holds significant yet underappreciated potential for tissue engineering. This review systematically summarizes the pathophysiology of clot formation, the key regulatory factors shaping its microenvironment, and its applications in both pre‐clinical and clinical settings ...
Gao‐peng Dang, Yu‐zhu Wang, Yi‐fei Wang, Que Bai, Jia‐xin Hao, Zhi‐ting Li, Xiao‐qing Cao, Yu Wei, Yue Feng, Ji‐hua Chen, Franklin R. Tay, Rui‐bing Wang, Jun‐ting Gu, Li‐na Niu   +13 more
wiley   +1 more source